Liquidia (LQDA) has drawn attention after a very large 52 week gain of more than 360%, along with a 100% technical "Buy" opinion and supportive analyst sentiment regarding future revenue and earnings projections.

At a latest share price of US$83.85, Liquidia’s recent pullback over the past week sits against a strong 30 day share price return of 6.23% and a very large 1 year total shareholder return of 317.79%. This points to momentum that has been building over an extended period.

If this kind of run in Liquidia has you looking for the next opportunity, it could be a good time to scan other high potential ideas using the Simply Wall St screener for 41 healthcare AI stocks

Liquidia now carries strong momentum and a growing rare disease franchise, yet the stock has surged to a market value of about US$7.5b. Does that price still reflect a sensible entry point today?

Most Popular Narrative: 18.6% Undervalued

Compared with Liquidia’s last close at $83.85, the most widely followed narrative points to a higher fair value of about $102.99 using a 7.11% discount rate.

Expanding use of inhaled treprostinil across broader fibrotic and inflammatory lung conditions such as IPF, PPF and PH-COPD is creating a multi-indication franchise opportunity that can meaningfully increase Liquidia’s addressable market and long term revenue base.

Want to understand what is sitting behind that higher fair value for Liquidia? The narrative leans on aggressive revenue scaling, sharply higher margins and a future earnings multiple that needs to compress materially from today’s level.

Result: Fair Value of $102.99 (UNDERVALUED)

However, this bullish Liquidia narrative still hinges on unresolved patent litigation and the company’s heavy reliance on YUTREPIA, both of which could materially alter the outlook.

Another View on Liquidia’s valuation

The most popular narrative paints Liquidia as 18.6% undervalued at $83.85. Yet on a simple P/S lens, the stock trades at 25.9x, far above the US Pharmaceuticals industry at 4.9x, the peer average at 12.5x, and even its own fair ratio of 13.3x. Is this a quality premium or just valuation risk building up?

Next Steps

If the mix of optimism and caution around Liquidia leaves you undecided, it could be worth reviewing the numbers now and forming your own stance using the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Liquidia?

If Liquidia has you thinking about what else could be on your radar, do not sit on the sidelines while other opportunities line up for attention.

• Target potential deep value by scanning companies that combine quality fundamentals with attractive pricing using the 53 high quality undervalued stocks.
• Strengthen your income stream by checking out stocks with robust yields and resilience through the 7 dividend fortresses.
• Prioritise resilience by reviewing companies screened for lower risk profiles via the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.